The company will not receive any of the proceeds from the sale of its common stock by the selling stockholders.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- IO Biotech Advances Cancer Vaccine Trials in Q1 2025
- IO Biotech: Promising Future with Strong Clinical Progress and Financial Backing
- Optimistic Outlook on IO Biotech: Promising Cancer Treatment Developments and Strategic Growth Moves
- IO Biotech price target raised to $14 from $12 at H.C. Wainwright
- IO Biotech reports Q1 EPS (34c) vs (30c) last year